R. Gottschalk

发表

Immunofluorescent and immunoperoxidase staining of antibodies to fibrous keratin. Improved sensitivity for detecting epidermal cancer cells.

J. Robinson, R. Gottschalk, 1984, Archives of dermatology.

The RD114/simian type D retrovirus receptor is a neutral amino acid transporter.

J. Rasko, I. Mazo, A. Miller, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Switching from natalizumab to fingolimod

X. Montalban, L. Kappos, H. Hartung, 2015, Neurology.

MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer

J. Blankenship, J. Gross, C. Mcmahan, 2016, Molecular Cancer Therapeutics.

Large Molecule Therapeutics MOR 209 / ES 414 , a Novel Bispeci fi c Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer

J. Blankenship, J. Gross, C. Mcmahan, 2016 .

The evaluation of a cell dispersion method of sputum examination

Todor A Popov, J. Dolovich, F. Hargreave, 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Abstract LB-199: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques

D. Jablonski, J. Gross, D. Bienvenue, 2019, Immunology.

Abstract 1786: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, induces potent T-cell activation, proliferation and cytotoxicity with limited cytokine release

J. Gross, Robert E. Miller, D. Bienvenue, 2018, Immunology.

Abstract 597: Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignancies

J. Blankenship, P. Pavlík, J. Gross, 2017 .

A polyphosphate kinase 1 (ppk1) mutant of Pseudomonas aeruginosa exhibits multiple ultrastructural and functional defects

A. Kornberg, P. Wood, R. Gottschalk, 2007, Proceedings of the National Academy of Sciences.

Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO)

X. Montalban, L. Kappos, N. Mueller-Lenke, 2013 .

CD18 Activation Epitopes Induced by Leukocyte Activation

D. Staunton, T. Kuijpers, C. R. Beals, 2001, The Journal of Immunology.

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

L. Kappos, G. Comi, R. Gold, 2013, Journal of Neurology.